{"id":688435,"date":"2022-09-23T09:03:19","date_gmt":"2022-09-23T13:03:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/"},"modified":"2022-09-23T09:03:19","modified_gmt":"2022-09-23T13:03:19","slug":"oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","title":{"rendered":"Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Sept.  23, 2022  (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on <strong>Wednesday, September 28, 2022<\/strong> at the NY Palace Hotel in New York City.<\/p>\n<p>James Breitmeyer, M.D, Ph.D., Oncternal\u2019s President and Chief Executive Officer, will participate in person in the \u201cMultiple Myeloma &amp; Lymphoma\u201d panel at 4:15pm (ET) at the Hubbard Room I, and the Company will host one-on-one meetings.<\/p>\n<p>\n        <strong>About Oncternal Therapeutics<\/strong><\/p>\n<p>Oncternal Therapeutics\u00a0is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer. The lead clinical program is\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h_cl0JA4w8HspnIPUQ5GPj2XOjowqS1gvOICxHZnZ1x63QN8ZMForgsWPBR-UiW6OocVZbCfRTRF7ZbnEa4eFjztQGz8ewH5Q95LZ8jMrzvbaIc9xEaQnXA5K2T62evk\" rel=\"nofollow noopener\" target=\"_blank\">zilovertamab<\/a>, an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1). Zilovertamab is being evaluated in an ongoing Phase 1\/2 study in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), and was recently amended to include patients with marginal zone lymphoma (MZL). Zilovertamab is also being evaluated in two investigator-initiated studies, including a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed\/refractory CLL, and in a Phase 1b study of zilovertamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). Oncternal is also developing\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cv0pqm4K87TMQUwYFsmDFMMQQJxTrvFbHbClt3LFZ2JrBdBV3uzpyi9-JDXGMDDdMXlecwfP2Jczw777Qhw_EWU-NUrnrHMuPs-Nh9hTOws=\" rel=\"nofollow noopener\" target=\"_blank\">ONCT-808<\/a>, an autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1. Oncternal submitted its first IND for ONCT-808 in August 2022, for the treatment of patients with relapsed or refractory aggressive B cell lymphoma, including patients who have failed previous CD19 CAR T treatment. The early-stage pipeline also includes\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PURvo6dYldJKuAFzlcSsQ3gF8hb2qIhGRLuc54JnjRVFASDGxpBGHjKBaHeus3-qJuifIMC2ilHlcQxlviupkC1qM6WLeZDeuvv2Ao34iAk=\" rel=\"nofollow noopener\" target=\"_blank\">ONCT-534<\/a>, a dual-action androgen receptor inhibitor (DAARI) that is undergoing final IND-enabling studies, as a potential treatment for castration resistant prostate cancer, including those with unmet medical need due to resistance to approved, standard of care androgen receptor inhibitors. More information is available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AB0nfQATHuKPNdlNwCgnfPALyquuyHRZ8szkb2ielcGPtlEXbf0yeQdE-8-oTri9xgqvmUOfV9z_vXRxau2AFlHxZZw4s3-dN6XDnwkHaNI=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/oncternal.com\/<\/a>.<\/p>\n<p>\n        <strong>Contact Information:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Richard Vincent<br \/>858-434-1113<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZShWCCmEEFROdpgZjZFNT6c1LK2Br3Q5kh_VPmGOl30YAs9epAgC55uWDVvwju6im0v-gtoVYNTivG5-dMHATprAafHcXdBks0xa2HyBSYc=\" rel=\"nofollow noopener\" target=\"_blank\"><u>rvincent@oncternal.com<\/u><\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Corey Davis, Ph.D. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>LifeSci Advisors \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>212-915-2577\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rYwr9xD58Cak0nZfgwOX_S57elcBhNY6ck4dJB65pMn3xUddefoaOZrbcsy9LY1xKPZ4W6BOiLrH0twzd-oBx5E3dWbTFv7DtzvDlVCtodYz9JoOw9CypOaQb5aO_H7h\" rel=\"nofollow noopener\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjAxNSM1MTY4MDkwIzUwMDA3NDE2MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDE1OWZhMzYtZTNmZi00ZGYwLTljM2EtM2Q2NDhhNzZhZmRiLTUwMDA3NDE2MQ==\/tiny\/Oncternal-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on Wednesday, September 28, 2022 at the NY Palace Hotel in New York City. James Breitmeyer, M.D, Ph.D., Oncternal\u2019s President and Chief Executive Officer, will participate in person in the \u201cMultiple Myeloma &amp; Lymphoma\u201d panel at 4:15pm (ET) at the Hubbard Room I, and the Company will host one-on-one meetings. About Oncternal Therapeutics Oncternal Therapeutics\u00a0is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-688435","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on Wednesday, September 28, 2022 at the NY Palace Hotel in New York City. James Breitmeyer, M.D, Ph.D., Oncternal\u2019s President and Chief Executive Officer, will participate in person in the \u201cMultiple Myeloma &amp; Lymphoma\u201d panel at 4:15pm (ET) at the Hubbard Room I, and the Company will host one-on-one meetings. About Oncternal Therapeutics Oncternal Therapeutics\u00a0is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal &hellip; Continue reading &quot;Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-23T13:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjAxNSM1MTY4MDkwIzUwMDA3NDE2MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference\",\"datePublished\":\"2022-09-23T13:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\"},\"wordCount\":389,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjAxNSM1MTY4MDkwIzUwMDA3NDE2MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\",\"name\":\"Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjAxNSM1MTY4MDkwIzUwMDA3NDE2MQ==\",\"datePublished\":\"2022-09-23T13:03:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjAxNSM1MTY4MDkwIzUwMDA3NDE2MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjAxNSM1MTY4MDkwIzUwMDA3NDE2MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","og_locale":"en_US","og_type":"article","og_title":"Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk","og_description":"SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference on Wednesday, September 28, 2022 at the NY Palace Hotel in New York City. James Breitmeyer, M.D, Ph.D., Oncternal\u2019s President and Chief Executive Officer, will participate in person in the \u201cMultiple Myeloma &amp; Lymphoma\u201d panel at 4:15pm (ET) at the Hubbard Room I, and the Company will host one-on-one meetings. About Oncternal Therapeutics Oncternal Therapeutics\u00a0is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal &hellip; Continue reading \"Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-23T13:03:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjAxNSM1MTY4MDkwIzUwMDA3NDE2MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference","datePublished":"2022-09-23T13:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/"},"wordCount":389,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjAxNSM1MTY4MDkwIzUwMDA3NDE2MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/","name":"Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjAxNSM1MTY4MDkwIzUwMDA3NDE2MQ==","datePublished":"2022-09-23T13:03:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjAxNSM1MTY4MDkwIzUwMDA3NDE2MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjAxNSM1MTY4MDkwIzUwMDA3NDE2MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-the-cantor-oncology-hematology-hemeonc-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology &amp; HemeOnc Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=688435"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688435\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=688435"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=688435"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=688435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}